The clinical progress is a positive step but the real catalyst will be the initiation of the Phase 3 study and eventual data readout. Monitor for Phase 3 start in H2 2026 and any additional funding announcements. The CFO promotion is routine and does not change the investment thesis.
Drug in focus
ARMP drug pipeline →AP-SA02
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2 complete; Phase 3 (registrational) planned for H2 2026
- Time to market
- Phase 3 (registrational) initiation expected H2 2026; pivotal data and any BLA/approval are realistically 2028-2030 at the earliest, contingent on Phase 3 success — AP-SA02 is years from commercialization.
- Next catalyst
- None dated
What to watchWatch for confirmation of the Phase 3 start (H2 2026 window) and any financing announcement, because the ~$5.07 stock's biggest near-term risks are cash runway and dilution, not trial mechanics. The real share-price binary, Phase 3 topline data, is likely 2+ years out, so treat the gap between the stock and the ~$17.5 mean analyst target as a long-dated optionality play, not a near-term event.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 20 $5.06entry
- T+1 · 4mo ago +1.98%α +1.14% · $5.16
- T+5 · 4mo ago −7.91%α −7.48% · $4.66
- T+20 · 3mo ago −11.46%α −15.58% · $4.48
- T+60 · 5w ago −38.74%α −43.58% · $3.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Armata Pharmaceuticals announced clinical, regulatory, and manufacturing progress for its lead candidate AP-SA02, including submission of the Phase 3 protocol to the FDA and completion of four engineering runs, keeping the Phase 3 superiority study on track for H2 2026. The company also disclosed a $2.5 million DoD award continuation (total $28.7M) and promoted David House to CFO. The clinical update is a positive catalyst but the company remains pre-revenue with no financial results reported.
Key Facts
- Phase 3 superiority protocol for AP-SA02 submitted to FDA; all End-of-Phase 2 meeting comments addressed.
- Four engineering runs of AP-SA02 completed; clinical trial material production is the next manufacturing step.
- Phase 3 study remains on track to initiate in the second half of 2026.
- DoD award continuation of $2.5 million brings total funding under the award to $28.7 million.
- David House promoted to CFO with base salary of $371,315, target bonus of 50%, and annual equity award intent of ~$300,000.
Financial Impact
No revenue or earnings reported. The DoD award provides $2.5M in additional non-dilutive funding, bringing total DoD support to $28.7M. The company is pre-revenue and will require additional capital to fund the Phase 3 study.
Risk Factors
- Clinical trial risk: Phase 3 may fail to meet endpoints.
- Funding risk: Company needs additional capital to execute Phase 3 study beyond existing DoD award.
- Regulatory risk: FDA may require additional data before accepting BLA.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (ARMP), Batch item 1 | 0001104659-26-084861 |
| Document: tm2620782d2_ex99-1.htm | 0001104659-26-084860 |
| Document: 0001104659-26-084861-index-headers.html | 0001104659-26-084861 |
| Document: 0001104659-26-084861-index.html | 0001104659-26-084861 |
| Document: 0001104659-26-084861.txt | 0001104659-26-084861 |
| 8-K Filing (ARMP), Batch item 6 | 0001104659-26-084860 |
| Document: tm2620782d1_8k.htm | 0001104659-26-084861 |
| Document: tm2620782d1_ex10-2.htm | 0001104659-26-084861 |
| Document: 0001104659-26-084860-index-headers.html | 0001104659-26-084861 |
| Document: 0001104659-26-084860-index.html | 0001104659-26-084861 |
| Document: 0001104659-26-084860.txt | 0001104659-26-084861 |
Track record
6 reports on ARMP
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +43.90% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $3.87 Now $2.99 −22.74% settles Dec 14
- Sep 23, 20267w ago 8-K Bullish 5/10 Entry $3.64 to $3.06 Now $2.99 −17.86% ▼ −15.93% −16.62% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Entry $5.55 to $3.63 Now $2.99 −46.13% ▼ −34.59% −36.86% vs SPY
- Jul 20, 202617w ago 8-K Bullish 5/10 Viewing Entry $5.06 to $4.48 Now $2.99 −40.91% ▼ −11.46% −15.58% vs SPY
- May 13, 202626w ago 8-K Bearish 6/10 Entry $8.20 to $7.58 Now $2.99 +63.54% ▲ +7.56% +6.70% vs SPY
- Apr 27, 202629w ago 8-K Neutral 3/10 Entry $11.00 to $8.17 Now $2.99 −72.82% ▼ −25.73% −30.68% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers